BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 22300273)

  • 1. Clinicopathologic study of E-cadherin/beta-catenin complex, and topoisomerase-II in a series of 71 liposarcoma cases.
    Gogou P; Pakos E; Batistatou A; Panelos I; Briasoulis E; Stefanou D; Apostolikas N; Tsekeris P
    World J Surg Oncol; 2012 Feb; 10():28. PubMed ID: 22300273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of E-cadherin, beta-catenin and topoisomerase IIalpha in leiomyosarcomas.
    Gogou PN; Batistatou A; Pakos EE; Apostolikas N; Stefanou D; Tsekeris PG
    Clin Transl Oncol; 2009 Aug; 11(8):548-51. PubMed ID: 19661031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beta-catenin accumulation and gene mutation in exon 3 in dedifferentiated liposarcoma and malignant fibrous histiocytoma.
    Sakamoto A; Oda Y; Adachi T; Saito T; Tamiya S; Iwamoto Y; Tsuneyoshi M
    Arch Pathol Lab Med; 2002 Sep; 126(9):1071-8. PubMed ID: 12204056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surgical resection of massive liposarcomas at the extremities: a 10-year experience in a referral musculoskeletal sarcoma unit.
    Ortiz-Ibáñez B; Amaya JV; Baixauli F; Angulo M; Mayordomo-Aranda E; Barrios C
    World J Surg Oncol; 2015 Jun; 13():206. PubMed ID: 26108965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of β-catenin and E-cadherin expression in Dukes B2 stage colorectal cancer with tissue microarray method. Is it a marker of metastatic potential in rectal cancer?
    Tóth L; András C; Molnár C; Tanyi M; Csiki Z; Molnár P; Szántó J
    Pathol Oncol Res; 2012 Apr; 18(2):429-37. PubMed ID: 21975680
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic values of osteopontin-c, E-cadherin and β-catenin in breast cancer.
    Pang H; Lu H; Song H; Meng Q; Zhao Y; Liu N; Lan F; Liu Y; Yan S; Dong X; Cai L
    Cancer Epidemiol; 2013 Dec; 37(6):985-92. PubMed ID: 24012693
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real time PCR analyses of expression of E-cadherin, alpha-, beta- and gamma-catenin in human breast cancer for predicting clinical outcome.
    Goyal A; Martin TA; Mansel RE; Jiang WG
    World J Surg Oncol; 2008 Jun; 6():56. PubMed ID: 18547424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What Are the Results of Resection of Localized Dedifferentiated Liposarcomas in the Extremities?
    Nakata E; Kunisada T; Hasei J; Nakahara R; Yanai H; Toji T; Inoue Ct H; Ozaki T
    Clin Orthop Relat Res; 2020 Nov; 478(11):2550-2561. PubMed ID: 33112583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. E-cadherin, b-catenin and topoisomerase II expression in rhabdomyosarcomas.
    Gogou PN; Batistatou A; Pakos EE; Apostolikas N; Stefanou D; Tsekeris PG
    J BUON; 2009; 14(2):323-4. PubMed ID: 19650189
    [No Abstract]   [Full Text] [Related]  

  • 10. Topoisomerase I and IIalpha protein expression in primary colorectal cancer and recurrences following 5-fluorouracil-based adjuvant chemotherapy.
    Tsavaris N; Lazaris A; Kosmas C; Gouveris P; Kavantzas N; Kopterides P; Papathomas T; Agrogiannis G; Zorzos H; Kyriakou V; Patsouris E
    Cancer Chemother Pharmacol; 2009 Jul; 64(2):391-8. PubMed ID: 19083133
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of immunohistochemical expression of topoisomerase alpha II, MIB-1, p53, E-cadherin, retinoblastoma gene protein product, and HER-2/neu in adrenal and extra-adrenal pheochromocytomas.
    Gupta D; Shidham V; Holden J; Layfield L
    Appl Immunohistochem Mol Morphol; 2000 Dec; 8(4):267-74. PubMed ID: 11127918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alteration of the E-cadherin/β-catenin complex predicts poor response to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) treatment.
    Yoo SB; Kim YJ; Kim H; Jin Y; Sun PL; Jheon S; Lee JS; Chung JH
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S545-52. PubMed ID: 23579873
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of topoisomerase II alpha, ki67, and p53 in primary non-muscle-invasive urothelial bladder carcinoma.
    Ben Abdelkrim S; Rammeh S; Ziadi S; Tlili T; Jaidane M; Mokni M
    J Immunoassay Immunochem; 2014; 35(4):358-67. PubMed ID: 24624938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epithelial-Mesenchymal Transition Markers β-catenin, Snail, and E-Cadherin do not Predict Disease Free Survival in Prostate Adenocarcinoma: a Prospective Study.
    Ipekci T; Ozden F; Unal B; Saygin C; Uzunaslan D; Ates E
    Pathol Oncol Res; 2015 Sep; 21(4):1209-16. PubMed ID: 26037169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis.
    Yan J; Liu XL; Han LZ; Xiao G; Li NL; Deng YN; Yin LC; Ling LJ; Yu XY; Tan CL; Huang XP; Liu LX
    Asian Pac J Cancer Prev; 2015; 16(2):823-9. PubMed ID: 25684532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liposarcomas in young patients: a study of 82 cases occurring in patients younger than 22 years of age.
    Alaggio R; Coffin CM; Weiss SW; Bridge JA; Issakov J; Oliveira AM; Folpe AL
    Am J Surg Pathol; 2009 May; 33(5):645-58. PubMed ID: 19194281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic importance of survivin, Ki-67, and topoisomerase IIα in ovarian carcinoma.
    Kucukgoz Gulec U; Gumurdulu D; Guzel AB; Paydas S; Seydaoglu G; Acikalin A; Khatib G; Zeren H; Vardar MA; Altintas A
    Arch Gynecol Obstet; 2014 Feb; 289(2):393-8. PubMed ID: 23974278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical Evaluation of Minichromosome Maintenance Protein 7 (MCM7), Topoisomerase IIα, and Ki-67 in Diffuse Malignant Peritoneal Mesothelioma Patients Using Tissue Microarray.
    Deraco M; Cabras A; Baratti D; Kusamura S
    Ann Surg Oncol; 2015 Dec; 22(13):4344-51. PubMed ID: 25777091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. E-cadherin and β-catenin expression in sebaceous eyelid adenocarcinomas.
    Li L; Zhang Z; Li B; Gao F; Li L; Jonas JB
    Graefes Arch Clin Exp Ophthalmol; 2011 Dec; 249(12):1867-73. PubMed ID: 21739269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive role of HER2/neu, topoisomerase-II-alpha, and tissue inhibitor of metalloproteinases (TIMP-1) for response to adjuvant taxane-based chemotherapy in patients with intermediate-risk breast cancer: results from the WSG-AGO EC-Doc trial.
    Erber R; Gluz O; Brünner N; Kreipe HH; Pelz E; Kates R; Bartels A; Huober J; Mohrmann S; Moustafa Z; Liedtke C; Möbus V; Augustin D; Thomssen C; Jänicke F; Kiechle M; Kuhn W; Nitz U; Harbeck N; Hartmann A
    Breast Cancer Res Treat; 2015 Apr; 150(2):279-88. PubMed ID: 25721604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.